Evidence map›Paper›PMID 33070986›Full record

ArticleArchives of medical research2021

COVID-19: Clouds Over the Antimicrobial Resistance Landscape.

Mauricio Rodríguez-Álvarez, Yolanda López-Vidal, José Luis Soto-Hernández, María Guadalupe Miranda-Novales, Karen Flores-Moreno, Samuel Ponce de León-Rosales

Open access · greenAbstract read
In one paragraph

Article in Archives of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Awareness and acceptance of COVID-19 vaccines and associated factors among pharmacy students in Zambia.Malawi medical journal : the journal of Medical Association of Malawi · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mauricio Rodríguez-ÁlvarezDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México. Electronic address: maurodriguez@unam.mx.
Yolanda López-VidalDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
José Luis Soto-HernándezDepartamento de Infectología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, México.
María Guadalupe Miranda-NovalesUnidad de Investigación en Análisis y Síntesis de la Evidencia, Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico.
Karen Flores-MorenoLaboratorio de Microbioma, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
Samuel Ponce de León-RosalesPrograma Universitario de Investigación en Salud, Universidad Nacional Autónoma de México, Ciudad de México, México.
Universidad Nacional Autónoma de México · MXCentro Medico Nacional Siglo XXI · MXInstituto Nacional de Neurología y Neurocirugía · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the increase in antimicrobial resistance (AMR) has been recognized as a real threat to human and animal health. It is a problem that has been given the highest priority, uniting nations in the fight against its causes and effects. Among the actions that have been implemented are: clinical and microbiological surveillance, promotion of rational and controlled use of antibiotics, AMR stewardship programs in hospitals, development of tools for rapid diagnosis of infectious diseases to establish prompt and adequate treatment, and radically improving vaccination strategies. The current COVID-19 pandemic has placed disproportionate demands on the healthcare infrastructure and economy worldwide, which will negatively impact on the availability of materials as well as the technical capacity for diagnosis, patient care, and treatment of both COVID-19 and non-COVID-19 patients. Disruptions to production and distribution chains will hamper the availability and usage of antibiotics, also interrupting several of the activities that have been implemented thus far to combat AMR, including detailed laboratory monitoring and reinforced vaccination programs. Here, we discuss the main aspects that should be considered with regard to AMR, that may be affected by the pandemic and propose some actions to counter them.

Indexed as

COVID-19 Drug TreatmentDrug Resistance, BacterialAnimalsAnti-Bacterial AgentsCOVID-19HumansPandemicsSARS-CoV-2Anti-Bacterial AgentsAnti-bacterial agentsAntimicrobial stewardshipCoronavirus pandemicDrug resistanceMicrobial

Identifiers

PMID33070986
PMCPMC7547601
OpenAlexW3092327734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.